ANKHD1 and non-small cell lung carcinoma: In NSCLC, the interaction between SMAD3 and Ankyrin Repeat and KH Domain Containing 1 (ANKHD1) was shown to be essential for the upregulation of cyclin dependant kinases (CDKs) and in particular CDK2, which was found to confer cisplatin resistance (Lv et al., 2021).